Orphan Drug Tax Credit Act of 2006

H.R. 5080, the Orphan Drug Tax Credit Act of 2006, aimed to accelerate the financial incentives available to pharmaceutical companies developing treatments for rare diseases. The bill proposed changing federal tax law to allow companies to claim tax credits for clinical testing costs as soon as they applied for "orphan drug" status, rather than waiting for the official designation to be granted. By providing earlier access to these credits, the bill sought to reduce the financial burden on researchers and potentially speed up the development of medications for patients with rare medical conditions.